Company intelligence / Profile preview

Inmagene LLC

San Diego, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

IMG-007 demonstrated dose-related clinical activity in alopecia areata with sustained improvement in SALT scores and was well-tolerated with no pyrexia or chills. In Phase 2a study, patients showed 21.7% mean reduction in SALT score at Week 36 for baseline scores 50-100, and 30.1% for scores 50-95.

Therapeutic areas: ImmunologyDermatology
Modalities: Monoclonal antibodySmall molecule
Industry: Biotech

Partnerships

HUTCHMED

Beyond the preview

Go deeper on Inmagene LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inmagene LLC.

Explore the full profile